Evidence map›Paper›PMID 39859407›Full record

ArticleInternational journal of molecular sciences2025

Olaparib Combined with DDR Inhibitors Effectively Prevents EMT and Affects miRNA Regulation in

Patrycja Gralewska, Łukasz Biegała, Arkadiusz Gajek, Izabela Szymczak-Pajor, Agnieszka Marczak, Agnieszka Śliwińska, Aneta Rogalska

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Patrycja GralewskaDepartment of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska Street, 90-236 Lodz, Poland.ORCID 0000-0002-2363-7827
Łukasz BiegałaDepartment of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska Street, 90-236 Lodz, Poland.ORCID 0000-0003-3896-8327
Arkadiusz GajekDepartment of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska Street, 90-236 Lodz, Poland.ORCID 0000-0003-3475-441X
Izabela Szymczak-PajorDepartment of Nucleic Acid Biochemistry, Medical University of Lodz, 251 Pomorska Street, 92-213 Lodz, Poland.ORCID 0000-0002-6545-579X
Agnieszka MarczakDepartment of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska Street, 90-236 Lodz, Poland.ORCID 0000-0003-3439-9032
Agnieszka ŚliwińskaDepartment of Nucleic Acid Biochemistry, Medical University of Lodz, 251 Pomorska Street, 92-213 Lodz, Poland.ORCID 0000-0002-6864-0704
Aneta RogalskaDepartment of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska Street, 90-236 Lodz, Poland.ORCID 0000-0002-4170-1693

Funding

National Science Center Sonata Bis 2019/34/E/NZ7/00056
6 · The paper itself

Abstract

Epithelial ovarian cancer (EOC) remains a leading cause of gynecologic cancer mortality. Despite advances in treatment, metastatic progression and resistance to standard therapies significantly worsen patient outcomes. Epithelial-mesenchymal transition (EMT) is a critical process in metastasis, enabling cancer cells to gain invasive and migratory capabilities, often driven by changing miRNA expression involved in the regulation of pathological processes like drug resistance. Targeted therapies like PARP inhibitors (PARPi) have improved outcomes, particularly in

Indexed as

Carcinoma, Ovarian EpithelialEpithelial-Mesenchymal TransitionMicroRNAsOvarian NeoplasmsPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsTumor Suppressor Protein p53Cell Line, TumorCell MovementCheckpoint Kinase 1DNA DamageDNA RepairFemaleGene Expression Regulation, NeoplasticHumansCheckpoint Kinase 1CHEK1 protein, humanMicroRNAsolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsTP53 protein, humanTumor Suppressor Protein p53DDR inhibitorsEMTmiRNAovarian cancerPARPi

Identifiers

PMID39859407
PMCPMC11766100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.